A broad expansion of patent families now covers Ether and Alkyl Phospholipid Compounds for treating cancer and imaging cancer stem cells, with protection for iopofosine I 131 and CLR-125 across Europe, China, Israel, Eurasia, and New Zealand.

The strategy emphasizes fortifying exclusivity for iopofosine I 131 and CLR-125 ahead of late-stage regulatory steps, with no financial terms or licenses disclosed.

The press release reiterates the Phospholipid Drug Conjugate delivery platform and focus on cancer-targeting treatments with improved efficacy and safety.

CEO James Caruso highlights momentum and the commitment to delivering new therapeutic options to cancer patients.

Caruso notes the strengthened IP fortification supports the company’s long-term commercial strategy and patient access goals.

Cellectar Biosciences has broadened its global IP estate to protect its cancer-targeting drug conjugates and enabling technologies, including the radiopharmaceuticals iopofosine I 131 and CLR-125.

New patents strengthen coverage for both therapeutic use and imaging, including dosing regimens for iopofosine I 131 and cancer stem cell imaging.

Context includes regulatory and funding momentum, with EMA guidance, FDA Breakthrough Therapy designation, and ongoing financing activity shaping the company's strategic progress.

The release notes risks such as reliance on future approvals, funding, collaborations, and general drug development uncertainties, and it states there are no current product revenues.

An FAQ clarifies patent scope, jurisdictions, EMA filing impact, targeted therapeutic areas, and notes the absence of disclosed commercial terms.

Background on the company’s pipeline, including CLR-125 and CLR-225, alongside the broader Phospholipid Drug Conjugate platform.

The company maintains focus on its PDC platform and pipelines—iopofosine I 131, CLR-125, and CLR-225—with notable designations and trials, including FDA Breakthrough and EMA PRIME for iopofosine I 131.